285 related articles for article (PubMed ID: 29856817)
1. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.
Pai M; Adhikari NKJ; Ostermann M; Heels-Ansdell D; Douketis JD; Skrobik Y; Qushmaq I; Meade M; Guyatt G; Geerts W; Walsh MW; Crowther MA; Friedrich JO; Burry L; Bellomo R; Brandão da Silva N; Costa Filho R; Cox MJ; Alves Silva S; Cook DJ;
PLoS One; 2018; 13(6):e0198285. PubMed ID: 29856817
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Burns KEA; Heels-Ansdell D; Thabane L; Kahn SR; Lauzier F; Mehta S; Ostermann M; Bhuptani P; Crowther MA; Finfer S; Cook DJ;
Can J Anaesth; 2023 Jun; 70(6):1008-1018. PubMed ID: 37310606
[TBL] [Abstract][Full Text] [Related]
6. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L;
Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Cook D; Douketis J; Meade M; Guyatt G; Zytaruk N; Granton J; Skrobik Y; Albert M; Fowler R; Hebert P; Pagliarello G; Friedrich J; Freitag A; Karachi T; Rabbat C; Heels-Ansdell D; Geerts W; Crowther M;
Crit Care; 2008; 12(2):R32. PubMed ID: 18315876
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
9. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
10. A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients.
Stelfox HT; Brundin-Mather R; Soo A; Parsons Leigh J; Niven DJ; Fiest KM; Doig CJ; Zuege DJ; Kushner B; Clement F; Straus SE; Cook DJ; Bagshaw SM; Sauro KM
Intensive Care Med; 2019 Feb; 45(2):211-222. PubMed ID: 30707246
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
13. VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.
Fernando SM; Tran A; Cheng W; Sadeghirad B; Arabi YM; Cook DJ; Møller MH; Mehta S; Fowler RA; Burns KEA; Wells PS; Carrier M; Crowther MA; Scales DC; English SW; Kyeremanteng K; Kanji S; Kho ME; Rochwerg B
Chest; 2022 Feb; 161(2):418-428. PubMed ID: 34419428
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
15. Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.
Worley S; Short C; Pike J; Anderson D; Douglas JA; Thompson K
J Spinal Cord Med; 2008; 31(4):379-87. PubMed ID: 18959355
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.
Cook DJ; Rocker G; Meade M; Guyatt G; Geerts W; Anderson D; Skrobik Y; Hebert P; Albert M; Cooper J; Bates S; Caco C; Finfer S; Fowler R; Freitag A; Granton J; Jones G; Langevin S; Mehta S; Pagliarello G; Poirier G; Rabbat C; Schiff D; Griffith L; Crowther M; ;
J Crit Care; 2005 Dec; 20(4):364-72. PubMed ID: 16310609
[TBL] [Abstract][Full Text] [Related]
17. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.
Lamontagne F; McIntyre L; Dodek P; Heels-Ansdell D; Meade M; Pemberton J; Skrobik Y; Seppelt I; Vlahakis NE; Muscedere J; Reece G; Ostermann M; Padayachee S; Alhashemi J; Walsh M; Lewis B; Schiff D; Moody A; Zytaruk N; Leblanc M; Cook DJ; ; ;
JAMA Intern Med; 2014 May; 174(5):689-96. PubMed ID: 24638843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
Park J; Lee JM; Lee JS; Cho YJ
J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients.
Davidson BL
Haemostasis; 2000; 30 Suppl 2():77-81; discussion 63. PubMed ID: 11251346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
